Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)
Conditions
Interventions
Lenalidomide
Chlorambucil
Locations
165
United States
California Cancer Associates for Research and Excellence cCARE
Escondido, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
The Hospital of Central Connecticut
New Britain, Connecticut, United States
Cancer Center of Central Connecticut
Southington, Connecticut, United States
University Hematology Oncology Inc.
Centralia, Illinois, United States
North Chicago VA Medical Center
North Chicago, Illinois, United States
Start Date
October 13, 2009
Primary Completion Date
March 31, 2014
Completion Date
May 9, 2018
Last Updated
July 9, 2019
NCT03110640
NCT00648739
NCT03757000
NCT01789255
NCT00867529
NCT00058240
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions